HIV stem cell therapy - Benitec/City of Hope

Drug Profile

HIV stem cell therapy - Benitec/City of Hope

Latest Information Update: 17 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Benitec Biopharma; City of Hope National Medical Center
  • Class Antivirals; Small interfering RNA; Stem cell therapies
  • Mechanism of Action Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections; Lymphoma

Most Recent Events

  • 21 Nov 2011 Pharmacodynamics data from a phase I trial in HIV infections released by Benitec
  • 04 Feb 2011 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top